Avita Medical (RCEL) Projected to Post Earnings on Thursday

Avita Medical (NASDAQ:RCEL) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Avita Medical to post earnings of ($0.2394) per share and revenue of $22.35 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Avita Medical (NASDAQ:RCEL) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $21.70 million during the quarter, compared to the consensus estimate of $20.25 million. On average, analysts expect Avita Medical to post ($0.98) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

Avita Medical Trading Down 0.5%

Shares of RCEL opened at $15.33 on Wednesday. The firm’s 50-day moving average price is $12.42 and its 200-day moving average price is $6.66. The firm has a market capitalization of $471.86 million, a price-to-earnings ratio of -10.65 and a beta of 2.03. Avita Medical has a 1-year low of $3.22 and a 1-year high of $16.90.

Analyst Ratings Changes

A number of equities analysts recently issued reports on RCEL shares. BTIG Research increased their price target on shares of Avita Medical from $11.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. TD Cowen reaffirmed a “buy” rating on shares of Avita Medical in a research report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Avita Medical in a report on Monday, September 21st. Lake Street Capital increased their target price on Avita Medical from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, August 28th. Finally, Wall Street Zen raised Avita Medical from a “sell” rating to a “hold” rating in a research report on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Avita Medical currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.20.

About Avita Medical

Avita Medical, Inc (NASDAQ: RCEL) is a regenerative medicine company focused on developing and commercializing therapies that use a patient’s own cells to help restore damaged skin and tissue. Its lead product is the RECELL System, an autologous cell-harvesting device designed to prepare a suspension of a patient’s skin cells at the point of care for application to wounds.

RECELL is used in the treatment of certain thermal burn wounds and other skin injuries. The system is intended to support wound healing and may reduce the amount of donor skin required for grafting by enabling clinicians to create a cell suspension from a small sample of the patient’s healthy skin.